1655 related articles for article (PubMed ID: 26945977)
1. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy.
He Y; Su Z; Xue L; Xu H; Zhang C
J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977
[TBL] [Abstract][Full Text] [Related]
2. Amino-functionalized mesoporous silica nanoparticles as efficient carriers for anticancer drug delivery.
He Y; Luo L; Liang S; Long M; Xu H
J Biomater Appl; 2017 Oct; 32(4):524-532. PubMed ID: 28776488
[TBL] [Abstract][Full Text] [Related]
3. A dual-functional HER2 aptamer-conjugated, pH-activated mesoporous silica nanocarrier-based drug delivery system provides in vitro synergistic cytotoxicity in HER2-positive breast cancer cells.
Shen Y; Li M; Liu T; Liu J; Xie Y; Zhang J; Xu S; Liu H
Int J Nanomedicine; 2019; 14():4029-4044. PubMed ID: 31213813
[No Abstract] [Full Text] [Related]
4. Natural gelatin capped mesoporous silica nanoparticles for intracellular acid-triggered drug delivery.
Zou Z; He D; He X; Wang K; Yang X; Qing Z; Zhou Q
Langmuir; 2013 Oct; 29(41):12804-10. PubMed ID: 24073830
[TBL] [Abstract][Full Text] [Related]
5. Zwitterionic mesoporous nanoparticles with a bioresponsive gatekeeper for cancer therapy.
Khatoon S; Han HS; Lee M; Lee H; Jung DW; Thambi T; Ikram M; Kang YM; Yi GR; Park JH
Acta Biomater; 2016 Aug; 40():282-292. PubMed ID: 27063494
[TBL] [Abstract][Full Text] [Related]
6. Development and in vitro evaluation of core-shell type lipid-polymer hybrid nanoparticles for the delivery of erlotinib in non-small cell lung cancer.
Mandal B; Mittal NK; Balabathula P; Thoma LA; Wood GC
Eur J Pharm Sci; 2016 Jan; 81():162-71. PubMed ID: 26517962
[TBL] [Abstract][Full Text] [Related]
7. In vivo distribution and antitumor activity of doxorubicin-loaded N-isopropylacrylamide-co-methacrylic acid coated mesoporous silica nanoparticles and safety evaluation.
Chen Y; Yang W; Chang B; Hu H; Fang X; Sha X
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):406-12. PubMed ID: 23816639
[TBL] [Abstract][Full Text] [Related]
8. Palmitoyl ascorbate and doxorubicin co-encapsulated liposome for synergistic anticancer therapy.
Yang Y; Lu X; Liu Q; Dai Y; Zhu X; Wen Y; Xu J; Lu Y; Zhao D; Chen X; Li N
Eur J Pharm Sci; 2017 Jul; 105():219-229. PubMed ID: 28526602
[TBL] [Abstract][Full Text] [Related]
9. pH-Triggered Surface Charge Reversed Nanoparticle with Active Targeting To Enhance the Antitumor Activity of Doxorubicin.
Du JB; Cheng Y; Teng ZH; Huan ML; Liu M; Cui H; Zhang BL; Zhou SY
Mol Pharm; 2016 May; 13(5):1711-22. PubMed ID: 26998644
[TBL] [Abstract][Full Text] [Related]
10. pH-sensitive polymeric nanoparticles for co-delivery of doxorubicin and curcumin to treat cancer via enhanced pro-apoptotic and anti-angiogenic activities.
Zhang J; Li J; Shi Z; Yang Y; Xie X; Lee SM; Wang Y; Leong KW; Chen M
Acta Biomater; 2017 Aug; 58():349-364. PubMed ID: 28455219
[TBL] [Abstract][Full Text] [Related]
11. EpCAM aptamer-functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery.
Xie X; Li F; Zhang H; Lu Y; Lian S; Lin H; Gao Y; Jia L
Eur J Pharm Sci; 2016 Feb; 83():28-35. PubMed ID: 26690044
[TBL] [Abstract][Full Text] [Related]
12. Co-delivery of Doxorubicin and Curcumin with Polypeptide Nanocarrier for Synergistic Lymphoma Therapy.
Guo W; Song Y; Song W; Liu Y; Liu Z; Zhang D; Tang Z; Bai O
Sci Rep; 2020 May; 10(1):7832. PubMed ID: 32398729
[TBL] [Abstract][Full Text] [Related]
13. Stepwise pH/reduction-responsive polymeric conjugates for enhanced drug delivery to tumor.
Yang S; Wang Y; Ren Z; Chen M; Chen W; Zhang X
Mater Sci Eng C Mater Biol Appl; 2018 Jan; 82():234-243. PubMed ID: 29025653
[TBL] [Abstract][Full Text] [Related]
14. A co-delivery system based on paclitaxel grafted mPEG-b-PLG loaded with doxorubicin: preparation, in vitro and in vivo evaluation.
Li Q; Lv S; Tang Z; Liu M; Zhang D; Yang Y; Chen X
Int J Pharm; 2014 Aug; 471(1-2):412-20. PubMed ID: 24905776
[TBL] [Abstract][Full Text] [Related]
15. A dual-sensitive mesoporous silica nanoparticle based drug carrier for cancer synergetic therapy.
Zhang J; Shen B; Chen L; Chen L; Meng Y; Feng J
Colloids Surf B Biointerfaces; 2019 Mar; 175():65-72. PubMed ID: 30522009
[TBL] [Abstract][Full Text] [Related]
16. Janus nanocarrier-based co-delivery of doxorubicin and berberine weakens chemotherapy-exacerbated hepatocellular carcinoma recurrence.
Zhang F; Jia Y; Zheng X; Shao D; Zhao Y; Wang Z; Dawulieti J; Liu W; Sun M; Sun W; Pan Y; Cui L; Wang Y; He K; Zhang M; Li J; Dong WF; Chen L
Acta Biomater; 2019 Dec; 100():352-364. PubMed ID: 31563690
[TBL] [Abstract][Full Text] [Related]
17. Lung cancer combination therapy: doxorubicin and β-elemene co-loaded, pH-sensitive nanostructured lipid carriers.
Cao C; Wang Q; Liu Y
Drug Des Devel Ther; 2019; 13():1087-1098. PubMed ID: 31118562
[No Abstract] [Full Text] [Related]
18. Enhanced cancer therapy with pH-dependent and aptamer functionalized doxorubicin loaded polymeric (poly D, L-lactic-co-glycolic acid) nanoparticles.
Saravanakumar K; Hu X; Shanmugam S; Chelliah R; Sekar P; Oh DH; Vijayakumar S; Kathiresan K; Wang MH
Arch Biochem Biophys; 2019 Aug; 671():143-151. PubMed ID: 31283911
[TBL] [Abstract][Full Text] [Related]
19. Contribution of carboxyl modified chiral mesoporous silica nanoparticles in delivering doxorubicin hydrochloride in vitro: pH-response controlled release, enhanced drug cellular uptake and cytotoxicity.
Li J; Du X; Zheng N; Xu L; Xu J; Li S
Colloids Surf B Biointerfaces; 2016 May; 141():374-381. PubMed ID: 26878288
[TBL] [Abstract][Full Text] [Related]
20. pH-Sensitive drug delivery system based on modified dextrin coated mesoporous silica nanoparticles.
Chen H; Zheng D; Liu J; Kuang Y; Li Q; Zhang M; Ye H; Qin H; Xu Y; Li C; Jiang B
Int J Biol Macromol; 2016 Apr; 85():596-603. PubMed ID: 26776872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
